Sorry!! The article you are trying to read is not available now.
BioTech/Pharma
Log In
Bussiness News
Politics And Regulation
Markets
The Economy
Editor's Pick
Trading And Investing
Stocks
ETFs
Fixed Income
Currencies
Earnings
Commodities
Options
Taxes
Personal Finance
How To Trade
How To Invest
sectors
Biotech/pharma
Consumer
Energy
Financial
Global Markets
Media
Precious Metals
Real Estate
Technology
Transportation
special features
Wall Of Worry
Random Thoughts
Sports Business
Minyanville Press
Hoofy & Boo
Radio
From The Buzz & Banter
Daily Recap
MV Education center
Video
t3 live subscriptions
Buzz And Banter
Cooper's Market Report
Techstrat Report
The Options Strategist
Minyanville
All Biotech/pharma Articles
Get
FREE MINYANVILLE
Newsletters & Alerts
Pfizer's Disappointing Performance Could Increase Pressure to Split the Company
By
Quartz
Apr 30, 2013 11:40 am
The world's biggest drugmaker missed analyst estimates, putting more pressure on the company to split.
Read this article
With Mental Health Emergency Care, Insurers Bank on Hassle Factor
Alex Brokaw
Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation
David Miller
Best Stocks: Biotech Still Holding Top Spots
StateOfTheMarkets.com
Best Stocks: Four New Names, Four New Buys
StateOfTheMarkets.com
Biotechs That Tackle Toxicity: Huge Global Market Awaits
Valorie Sands
Chart of the Day: Expect UnitedHealth Stock to Hit All-Time Highs
RiskReversal.com
David & Goliath: Small Biotechs Wage a Big Fight Against the Superbug
Valorie Sands
Recommendations
Archive
March, 2018
February, 2018
January, 2018
December, 2017
November, 2017
October, 2017
September, 2017
August, 2017
July, 2017
June, 2017
May, 2017
April, 2017
TICKERS
PFE
MRK
JNJ
BMY
GSK
DNDN
GILD
VRTX
AMGN
LLY
ARNA
BIIB
See All Tickers »